Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 22, 2026
Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Fineline Cube Jun 22, 2026
Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Fineline Cube Jan 28, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from its Phase II clinical trial (CT388‑103)...

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026

The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly...

Company Drug

Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia

Fineline Cube Jan 28, 2026

Novartis (NYSE: NVS) announced that Leqvio (inclisiran) has received an additional indication approval from the National...

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739), a China‑based contract development and manufacturing organization (CDMO), announced...

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Fineline Cube Jan 28, 2026

China’s State Council this week issued the Implementation Regulations of the Drug Administration Law, a...

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received National Medical Products Administration (NMPA)...

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-5346, the centerpiece of a USD 1.97 billion...

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026

IVD Medical Holding Ltd (HKG: 1931), a China‑based in vitro diagnostic specialist, announced the launch...

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials

Fineline Cube Jan 28, 2026

Betta Pharmaceuticals (SHE: 300558) announced that the National Medical Products Administration (NMPA) has approved the...

Company Drug

Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma

Fineline Cube Jan 28, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that LBL-034, a GPRC5D/CD3 bispecific antibody (BsAb) T‑cell...

Policy / Regulatory

NMPA Suspends Two Indian Pharma APIs Over GMP Violations

Fineline Cube Jan 27, 2026

China’s National Medical Products Administration (NMPA) announced enforcement actions against two India‑based active pharmaceutical ingredient...

Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026

Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...

Company Drug

Innovent Biologics Secures FDA Fast Track for IBI3003 Trispecific Antibody in Multiple Myeloma

Fineline Cube Jan 27, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026

Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...

Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026

Acrobiosystems Co., Ltd. made its initial public offering filing to the Hong Kong Stock Exchange,...

Company Drug

Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline

Fineline Cube Jan 27, 2026

Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong...

Medical Device

Bio-heart Secures Indonesia Approval for Iberis RDN System

Fineline Cube Jan 27, 2026

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its...

Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Fineline Cube Jan 27, 2026

BioArctic AB (OTCMKTS: BRCTF) partner Eisai (TYO: 4523) announced submission of a proposed Marketing Authorisation Variation...

Company Drug

Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy

Fineline Cube Jan 27, 2026

Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients...

Company

ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO

Fineline Cube Jan 27, 2026

The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer (NYSE: PFE) and with participation...

Posts pagination

1 … 71 72 73 … 686

Recent updates

  • Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch
  • IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma
  • Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings
  • Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners
  • Roche’s Lunsumio-Polatuzumab Combination Accepted for FDA Review in Relapsed/Refractory Large B-Cell Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch

Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.